By using this website, you agree to the storing of cookies on your device. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Cookie Policy.

Slingshot Biosciences Intellectual Property

Copyright Information

Unless otherwise specified, the entire content included in this site, including but not limited to the text, graphics, images, and code, as well as any individual images or photographs, are copyrighted under the United States and other copyright laws, and are the exclusive property of Slingshot Biosciences,TM Inc. Any use, including any reproduction, distribution, display, or transmission of the content of this site or individual images or photographs on this site is strictly prohibited.

Trademark Information

All trademarks, service marks, trade names, logos and product names of Slingshot Biosciences, Inc. used on this site are trademarks or registered trademarks of Slingshot Biosciences, Inc. in the U.S.A. and other countries. This includes but is not limited to: SLINGSHOT BIOSCIENCES, BEAM, TRUCYTES, FLOWCYTES, SPECTRACOMP and VIACOMP.

Patent Marking

Slingshot Biosciences, Inc. products, including but not limited to SpectraComp, ViaComp, TruCytes, FlowCytes products, may be covered by one or more of the following patents in the U.S. and internationally. This website page is provided to satisfy the virtual patent marking provisions of various jurisdictions, in particular it is intended to serve as notice under 35 U.S.C. ยง 287(a). Items listed below may be sold individually or as part of a combination product. Additional patent applications may also be pending in U.S. and internationally.

USA:
9,714,897
9,915,598
10,481,068
10,753,846
10,942,109

Australia
2016218254

Japan
6692834

Taiwan
105104380

Patent applications are pending in Hong Kong, Canada, Korea, the European Union, Japan and the USA.